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Disordered transcriptomes of cancer encompass
direct effects of somatic mutation on transcription,
coordinated secondary pathway alterations, and
increased transcriptional noise. To catalog the rules
governing how somatic mutation exerts direct tran-
scriptional effects, we developed an exhaustive
pipeline for analyzing RNA sequencing data, which
we integrated with whole genomes from 23 breast
cancers. Using X-inactivation analyses, we found
that cancer cells are more transcriptionally active
than intermixed stromal cells. This is especially true
in estrogen receptor (ER)-negative tumors. Overall,
59% of substitutions were expressed. Nonsense
mutations showed lower expression levels than ex-
pected, with patterns characteristic of nonsense-
mediated decay. 14% of 4,234 rearrangements
caused transcriptional abnormalities, including
exon skips, exon reusage, fusions, and premature
polyadenylation. We found productive, stable tran-
scription from sense-to-antisense gene fusions and
gene-to-intergenic rearrangements, suggesting that
these mutation classes drive more transcriptional
disruption than previously suspected. Systematic2032 Cell Reports 16, 2032–2046, August 16, 2016 ª 2016 The Autho
This is an open access article under the CC BY license (http://creativeintegration of transcriptome with genome data re-
veals the rules by which transcriptional machinery in-
terprets somatic mutation.INTRODUCTION
Somatic mutation underpins the development of cancer, and
most solid tumors have thousands to tens of thousands of point
mutations, coupled with tens to hundreds of genomic rearrange-
ments and copy-number changes (Garraway and Lander, 2013;
Stratton et al., 2009). Small numbers of these, known as driver
mutations, dysregulate the fundamental cellular processes
involved in normal tissue homeostasis, and they confer a selec-
tive advantage to the clone. A critical point is that Darwinian se-
lection acts on phenotype, and so, for a somatic mutation to
drive cancer, it must manifest a phenotypic effect. Transcription
is the primary conduit by which changes in the genomic code are
translated into cellular phenotype, with the corollary that it is a
necessary criterion of driver mutations that they directly induce
a change in transcript structure. Altered transcript structure
can take many forms, including the creation of fusion genes by
genomic rearrangement, interference with RNA splicing at
mutated splice sites, alteration of the codon sequence for
missense substitutions, and over- or under-expression of genes
through copy-number alterations or mutation in regulatory
regions.rs.
commons.org/licenses/by/4.0/).
Beyond the primary and direct effects of somatic mutation
on transcript structure, there may be a series of downstream,
secondary alterations in the transcriptome occurring as a
consequence of the primary effect. Most studies of the tran-
scriptome in cancer, including those from large-scale efforts
such as The Cancer Genome Atlas (TCGA) (Kandoth et al.,
2013; Cancer Genome Atlas Network, 2012a), have evaluated
these second-order effects, concentrating predominantly on
the magnitude of gene expression using microarray technology
(Curtis et al., 2012; Perou et al., 2000; Sørlie et al., 2001) or
RNA sequencing (RNA-seq) (Shah et al., 2009; Cancer
Genome Atlas Research Network, 2012b). They have revealed
large-scale disturbances of transcriptional regulation in most
cancers, with expression profiles for many hundreds of genes
differing from profiles of normal cellular counterparts. Within a
tumor type, similarities in transcriptional profiles across indi-
viduals allow the disease to be sub-classified into several
groups, many of which have biological, therapeutic, and prog-
nostic significance. In some cases, these changes can be
correlated with underlying driver mutations, such as ERBB2
amplification in breast cancer (Sørlie et al., 2001) or specific
fusion genes in acute myeloid leukemia (Valk et al., 2004).
While these studies have concentrated on mRNA profiles,
similar observations are beginning to emerge from studies of
microRNA transcription (Dvinge et al., 2013), long non-coding
RNA levels, and even expression of pseudogenes (Kalyana-
Sundaram et al., 2012).
Although it is a necessary criterion for a driver mutation to
directly induce modification of transcript structure, it is not suffi-
cient. Many mutations that do not confer selective advantage,
so-called passenger mutations, also generate phenotypic con-
sequences, but consequences of no benefit to the cell. Initial
studies correlating RNA-seq data with genomic change in can-
cer have reported some of these direct effects, especially for
coding point mutations or canonical fusion transcripts (Shah
et al., 2009), but there has been little systematic effort to
describe, measure, and quantify first-order transcriptional con-
sequences across all classes of somatic mutation found in
well-annotated cancer genomes.
Here, we report a comprehensive analysis of the primary
transcriptional alterations induced by somatic mutation in a
set of 23 breast cancers. We found that the genomic variants
carried by the cancer cells can have subtle or profound effects
on the transcriptome, many of which could not easily be pre-
dicted from the genome, many of which amalgamate several
in cis mutations, and many of which are stably expressed at
high levels.
RESULTS
Whole-Genome Sequencing and RNA-Seq from 23
Breast Cancer Samples
To understand the inter-relationships between somatic muta-
tion and the transcriptome, we matched RNA-seq data to
whole-genome-sequencing data in 23 breast cancer samples.
Of these, 14 were primary breast cancers and nine were
matched breast cancer cell lines. For the genomes, tumor sam-
ples were sequenced to 403 coverage and matched normalsamples to 303 coverage, with somatically acquired substitu-
tions, insertions or deletions (indels), genomic rearrangements,
and copy-number changes called by a suite of in-house algo-
rithms. The whole-genome sequencing for the 14 primary breast
cancer samples has been described previously (Nik-Zainal
et al., 2012a, 2012b), although improvements in our bioinfor-
matics algorithm allowed us to update the list of genomic rear-
rangements (Table S1). The high-coverage genome-sequencing
data for eight breast cancer cell lines are reported for the first
time here (somatic mutations in Table S2); for the other line
(HCC2157), we used exome and low-coverage whole-genome
data reported previously (Nik-Zainal et al., 2012b; Stephens
et al., 2009).
RNA-seq was performed on the 23 breast cancer samples
together with eight organoids freshly isolated from uncultured
normal breast milk ducts (Choudhury et al., 2013).We developed
a suite of algorithms to exhaustively characterize the cancer
transcriptome; in so doing, we aimed to wring maximum detail
on the structure of cancer transcripts from RNA-seq data. Previ-
ous work has examined gene and mutation expression alone or
has focused exclusively on one facet of transcript structure (such
as fusion genes or alternative splicing) without allowing for the
discovery of multiple or complex events or the involvement of
the antisense strand. We implemented a seed-and-extend map-
ping algorithm to find reads that span different regions of the
genome, and then we developed a discordant pair analysis algo-
rithm, drawing these results together with a set of methods to
arrange the results into biologically meaningful categories
(described in detail in the Experimental Procedures and
Figure S1).
The primary advantage of our software pipeline, which we call
RNA Architect, is the comprehensive detection of transcriptional
alterations, including events missed by other methods. These
would include compound events present in cis, such as fusion
transcripts involving alternative splice forms and exon skips
with cryptic splice sites; internal exon shuffling (reusage); post-
transcriptional modifications, such as early polyadenylation
sites; and non-canonical transcript junctions, for example, fu-
sions between the sense and antisense of different genes or
those involving lowly expressed transcripts that are not present
in reference databases. While there exists a number of methods
for aligning RNA-seq and detecting fusions (Asmann et al., 2011;
Chen et al., 2012; Kim and Salzberg, 2011; McPherson et al.,
2012; Swanson et al., 2013; Torres-Garcı´a et al., 2014), there
have been few efforts to simultaneously characterize the cancer
transcriptome for multiple types of alterations.
Transcription Derived from Cancer Cells and Stromal
Cells
Tumors are comprised of a complex admixture of clonal cancer
cells and polyclonal stromal cells. In breast cancer, the propor-
tion of cells deriving from the malignant clone is typically 30%–
70%, although the remaining cells encompass endothelial cells,
supporting connective tissue, inflammatory cells, lymphocytes,
and normal breast epithelium. RNA samples extracted from pri-
mary breast cancers, therefore, represent an amalgam of gene
expression signatures derived from multiple cell lineages, com-
pounding interpretation.Cell Reports 16, 2032–2046, August 16, 2016 2033
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In females, a randomly selected X chromosome is inactivated
in each cell of the inner cell mass of the early blastocyst, and this
choice is transmitted through every subsequent cell division.
Since cancer cells are derived from a single ancestral cell, all
have the same X chromosome inactivated (Fialkow et al.,
1981), whereas the polyclonal stromal tissue has a broadly
equivalent fraction of cells with maternal or paternal X chromo-
somes inactivated. As a result, genes undergoing X inactivation
with heterozygous germline SNPs are monoallelically expressed
in the cancer cells and biallelically expressed in stromal cells
(Figure S2).
We identified heterozygous germline SNPs in expressed re-
gions of the X chromosome from the genomic sequencing data
across the 14 primary breast cancers, excluding regions that
were not diploid in the cancer. From the RNA-seq data, we
extracted the number of reads expressing each allele. In
PD4120a, for example, 385 heterozygous SNPs on the X chro-
mosome were expressed. The observed reference/variant ratio
in the RNA-seq data at each position ranged from transcripts
whose expression was exclusively monoallelic through tran-
scripts with skewed ratios to genes that had an approximately
equal expression of both alleles (Figure 1A). Respectively, these
three scenarios represent genes expressed exclusively in cancer
cells, genes expressed in both cancer and stromal cells, and
genes expressed exclusively in stromal cells.
We developed a statistical algorithm based on a Bayesian hi-
erarchical Dirichlet process to model the fraction of transcripts
along the X chromosome derived from cancer cells (Experi-
mental Procedures). For each heterozygous SNP, the algorithm
estimates what fraction of reads covering that base derived from
cancer cells, allowing for the uncertainty of whether the refer-
ence or variant allele is inactivated in the tumor (Figure 1B; Fig-
ure S2B). When amalgamated across SNPs from the whole X
chromosome, we can estimate the relative contribution of stro-
mal and cancer cells to transcription as a general distribution
(Figure 1C).
We found a considerable portion of transcripts that were
exclusively expressed in cancer cells among the 14 patients
in which primary breast cancer samples were sequenced (Fig-
ure 1D; Figure S2C). Strikingly, many tumors had a set of tran-
scripts that were 80%–90% derived from cancer cells and
10%–20% from stromal cells, whereas there were only small
numbers of genes expressed predominantly from stromalFigure 1. Separating Expression of X-Linked Genes into Stromal and T
(A) Fraction of RNA-seq reads reporting reference allele of heterozygous germline
reflects the level of expression.
(B) Fraction of transcripts derived from tumor cells for each heterozygous germli
(C) Estimated distribution and 95% posterior intervals for relative gene expressio
density of genes; the x axis reports the fraction of transcripts for each gene derivin
100% derived from cancer cells and 0%–20% from stromal cells, with only a sm
(D) Distributions for several selected primary cancers are shown, as for (C).
(E) Overall fraction of transcripts derived from cancer cells (y axis) compared to
genomic DNA using copy-number profiles) is shown.
(F) Increased expression of the mutated allele in ER as compared to ER+ breast
sequenced as part of TCGA are shown. Plotted on the y axis is the variant allele
(G) Inverse relationship between each tumors’ expression of Estrogen Receptor
0.2433, p < 0.0001). Using linear regression analysis to model this relationship, w
are expressed.cells. We also could integrate all the data for a given patient
to estimate the overall fraction of transcripts derived from tu-
mor cells, and we could compare this to the overall fraction
of cancer cells in the sample estimated from the genomic
DNA (Figure 1E). This indicates that cancer cells contribute a
higher fraction of transcripts in the RNA sample than expected
for their cellular proportion, indicating that they are more tran-
scriptionally active than the stromal cells. Thus, even though
cancer cells comprise, on average, 30%–70% of all cells in
a breast tumor, they contribute 70%–90% of all RNA
molecules.
Strikingly, it appeared that the magnitude of the difference
between transcriptional output of cancer cells and stromal
cells was greater in estrogen receptor-negative (ER-ve) tumors
than in ER-positive tumors (Figure 1E). The difference in ER-ve
also was seen in an independent set of primary breast cancers
(661 ER positive and 176 ER-ve), using a larger set of variants
(38,337 somatic substitutions; Figure 1F; cosmic census
genes with high variant allele fraction difference in ER-ve can-
cers; Table S3). Further, it appears that the number of muta-
tions expressed in a breast tumor, a measure of its transcrip-
tional output, is significantly associated with the amount of
estrogen receptor it expresses (0.2433, p < 0.0001). That
is, tumors with high levels of ER express fewer mutations
than cancers with low ER. We formally modeled this relation-
ship and determined that, for every 1% decrease in ESR1
expression, 15 more mutations are expressed in breast cancer
(Figure 1G).
Effects of Point Mutations on Structure of the
Transcriptome
We identified all somatically acquired base substitutions in
the 23 breast cancers that were in expressed regions, and we
compared the fraction of sequencing reads reporting the mutant
allele in the transcriptome to that expected from the genome
(Figures S3A and S3B). As anticipated, there was a strong overall
correlation between the genomic and transcriptomic variant
allele fraction (r2 = 0.59; p < 0.0001). Overall, 6,980 substitutions
were found in exons, of which 4,751 were expressed to a suffi-
cient degree that five or more sequencing reads covered the
base. Of the 6,980 variants identified in exonic regions of the
23 samples, 4,152 (59%) had discernible expression in the cor-
responding transcriptome.umor Compartments
SNPs on the X chromosome in one of the patients (PD4120a). The depth of color
ne SNP shown in (A), estimated with a Bayesian Dirichlet process, is shown.
n in cancer versus stromal cells for PD4120a. The y axis reports the estimated
g from cancer cells. Thus, the transcripts for most genes in PD4120a are 80%–
all peak of genes predominantly expressed from stromal cells.
the estimated proportion on tumor cells in the sample (x axis, estimated from
cancer transcriptomes (plotted relative to the genome). Primary breast cancers
fraction in the transcriptome, relative to the genome (VAFdiff).
1 (ESR1) and the overall expression of its point mutations (shown as VAFdiff;
e determined that, for every 1% drop in ESR1,15 additional point mutations
Cell Reports 16, 2032–2046, August 16, 2016 2035
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Figure 2. The Effect of Somatic Point Muta-
tions on Expression and Aberrant Splicing
(A) Comparison of the variant allele fractions in
the transcriptome to the genome, for all classes
of point mutation. The squared correlation coeffi-
cient between the genome and transcriptome is in
parentheses. Only expressed coding changes are
shown (five or more times coverage).
(B) Variant allele fractions in the transcriptome
relative to the genome. Nonsense mutations
>50 bp from the terminal 30 exon-intron junction
are the only variants to show a significant
difference.
(C) Positional effect of mutations on aberrant
splicing is shown.There were some differences in the transcription levels of
base substitutions according to the predicted consequence on
the protein (Figure 2A). We found that silent, missense, and
UTR mutations have the same strong correlation between
variant allele fractions in the genome and transcriptome,
whereas nonsense mutations have a weaker relationship.
Indeed, nonsense mutations had a significantly lower expres-
sion than predicted from the genome compared to other classes
of mutation (p < 0.0001).
Several reasons could explain the lower expression of
nonsense mutations. Nonsense-mediated decay could selec-
tively target transcriptswith nonsensemutations for degradation.
Nonsense-mediated decay depends on the cell distinguishing a
premature termination codon from a proper termination codon.2036 Cell Reports 16, 2032–2046, August 16, 2016Generally, stop signals in the last exon
are considered proper, whereas those
appearing >50–55 bp upstream of the
last exon-exon junction, and therefore
upstream of the exon-junction complex,
are more likely to be targeted for
nonsense-mediated decay (Nagy and
Maquat, 1998). We did find evidence for
nonsense-mediated decay, since the
decreased allele fraction in transcriptome
relative to genome was significantly more
pronounced for nonsense mutations if
they were >50 bp upstream of the last
exon-exon splice junction (p = 0.003;
Figure 2B).
Another possible explanation for the
low expression of nonsense mutations is
that they are tolerated only in genes not
expressed in the cancer cells; those
occurring in important genes would be
subject to negative selection. To explore
this possibility, we compared the expres-
sion levels from the organoids of normal
breast epithelium for genes mutated in
the cancer samples. We found no clear-
cut differences across the mutation cate-
gories for whether the mutated genes
were expressed in normal breast epithe-lial cells (Figure S3C), suggesting that this reason does not
explain the lower expression levels of nonsense mutations.
Therefore, it appears as if only nonsense-mediated decay ex-
plains the lower expression of these mutations.
Point mutations can directly affect RNA splicing, leading to
retention of introns (especially for splice donor site mutations),
exon skipping (splice acceptor site variants), or enhancement
of alternative splice sites (other exonic or intronic variants). We
assessed the frequency of alternative splicing events related to
somatic base substitutions, where the splice isoform was not
present in the normal breast organoids (Figure 2C). We found
no excess of abnormal splice isoforms associated with muta-
tions in exons near splice sites. We found that mutations
affecting the essential splice sites at +1, +2, and 1 into the
intron were the most strongly associated with altered splicing in
the given sample (p = 0.002, p = 0.0001, and p = 0.0005, respec-
tively, compared to intronic mutations >100 bp from the nearest
exon). Nonetheless, despite this enrichment, the actual fraction
of suchmutations at essential splice sites that generated detect-
able abnormal splice isoforms was <25%, suggesting that most
such variants do not affect splicing or the transcripts that result
are rapidly degraded. Further into the introns, there were some
positions at which mutations caused significantly more splicing
abnormalities than expected (49, p = 0.04; +23, p =
0.02; +46, p = 0.01; and +60, p = 0.003). Strikingly, several of
these isolated positions coincided with sites of reduced germline
polymorphism. For example, the regions from +21 to +26 and
from +45 to +50 both showed strongly significant reductions in
genetic variation in the germline (Lomelin et al., 2010), suggest-
ing that functional motifs regulating splicing may reside in these
sites.
Direct Effects of Genomic Rearrangements on
Transcriptome Structure
Genomic rearrangements contribute to cancer development
through several mechanisms, including changing the copy
number of a gene or genes, altering the regulatory apparatus
of a gene, and reorganizing the exon sequence within a gene
or between two genes. To evaluate effects of genomic rear-
rangements on transcriptome structure, we classified somati-
cally acquired structural variants across two variables: type of
rearrangement (deletion, tandem duplication, inverted, or inter-
chromosomal) and whether genes were involved at either side
of the breakpoint (gene-to-gene, same or opposite orientation;
gene-to-intergenic; within gene, same or different introns; or
local genomic complexity, where more than one rearrangement
affected one or other gene). For each rearrangement, we identi-
fied any aberrant transcript arising from the genes involved,
excluding any splice form seen in the normal breast organoids
or the Ensembl database.
Even in cancer samples without rearrangements affecting a
given gene, we often found evidence for previously undocu-
mented transcripts, such as novel splice forms, read-through
transcripts, and non-canonical splice acceptor or donor sites.
It is, therefore, difficult to argue categorically for a given rear-
rangement that an abnormal transcript arises as a direct conse-
quence of the genomic change. Instead, since we aremore inter-
ested in the overall patterns of abnormal transcription caused
by somatic mutation, we studied the excess of aberrant tran-
scription associated with the different categories of genomic
rearrangement. The normalized expression level of aberrant
transcripts was ranked for the sample in which the rearrange-
ment was found, relative to aberrant transcripts in the other 22
cancer samples (Figure 3A). If a given rearrangement had no
effect on transcription, then the ranking would be effectively uni-
formly distributed across ranks 1–23, whereas those rearrange-
ments that caused significant alterations to transcriptome struc-
ture would garner the highest rank.
There is a clear excess of genomic rearrangements with the
maximum ranking for aberrant transcription. Using maximum
likelihood methods, we estimated that this excess represents
11.6% (95% confidence interval, 10.4%–12.8%) of 4,234 genicrearrangements identified in these samples (Supplemental
Experimental Procedures); that is, 11.6% of somatically ac-
quired genomic rearrangements affecting genes are associated
with evidence of aberrant transcription beyond the background
rate in breast cancer. This varied by the pattern of genes at the
breakpoint, with particularly high rates observed for intragenic
rearrangements leading to alterations of exon order but minimal
evidence for aberrant transcription arising from rearrangements
confined to a single intron within a gene.
We observed a number of different patterns of aberrant tran-
scription (Figure 3B). These included fusion transcripts between
two genes, alternative splicing events, exon reusage, and pre-
mature polyadenylation. To some extent, the alterations in tran-
script structure could be predicted by the underlying genomic
rearrangements, such as exon skips caused by intragenic dele-
tions, but inmany cases the abnormalities were rather surprising.
In the following sections, we review the transcriptional conse-
quences associated with each of the major classes of genomic
rearrangement.
Within-Gene Rearrangements
Across the 23 breast cancer samples studied, we identified 631
intrachromosomal rearrangements confined to a single intron of
a gene, mostly deletions and tandem duplications (358 and 192,
respectively). Of these, we believe that very few had discernible
consequences on transcriptome structure, since there was no
apparent excess of such rearrangements generating the highest
rank for transcriptional aberration across samples (Figure 3A).
For the 38 rearrangements with highest rank, the most common
effect on transcript structure was to skip an exon (69%;
Figure 3B).
As expected, rearrangements that went across different in-
trons of the same gene had a considerably greater effect on tran-
script structure than those confined to one intron (Figure 3A). In
general, the transcriptome reflected the rearranged gene struc-
ture in an entirely predictable way, with deletions causing exon
skips and tandemduplications causing exon reusage (Figure 3B).
Of 341 genomic rearrangements involving different introns of the
same gene, 84 had the highest rank for transcriptional abnormal-
ity. Of these 84, 23 (27%) caused multiple disruptions in the tran-
scriptome at the same gene, mostly alternative splice isoforms.
Particularly common were exon skips of not just deleted exons
but neighboring exons as well. We found a complex transcrip-
tional abnormality in the histone H3-lysine-4 (H3K4)-methyl-
transferase MLL3 (KMT2C) involving an exon reusage using a
cryptic donor (Figure S6A). Follow-up experiments using TCGA
data revealed an additional 13 samples with abnormalities in
MLL3 (Figure S6B).
Gene-to-Gene Rearrangements in the Same
Transcriptional Orientation
We identified 205 somatic rearrangements that juxtaposed one
or more exons of two protein-coding genes in the same tran-
scriptional orientation; these would be predicted to generate
fusion genes. Overall, 70 (34%) of these were expressed (Fig-
ure 4A). As seen with the within-gene rearrangements, the tran-
scriptome structure was generally as predicted from the
genomic rearrangement, although more than one splice isoformCell Reports 16, 2032–2046, August 16, 2016 2037
AB
Figure 3. The Transcriptional Conse-
quences of Structural Rearrangement
All rearrangement types and their position with
respect to genes are shown as a matrix in both
panels. Transcriptional disruptions caused by
each rearrangement type are shown within the
matrix.
(A) Number of rearrangements causing aberrant
transcription. Normalized aberrant transcription
levels were contrasted between the sample that
contained the rearrangement and all others.
Plotted is the aberrant transcription ranking of
the rearranged sample relative to all others for the
same genes (red bars). The pie charts show the
fraction of all rearrangements of that type that are
excess in the final rank compared to the number
expected under a uniform distribution.
(B) Types of aberrant transcriptional events
caused by rearrangements are shown.was present in 20 of the 70 rearrangements, increasing the range
of transcripts observed (Figure 4B). The only recurrent fusion
transcript that we observed in this cohort was between
NCOA7 and TRMT11, adjacent genes on chromosome 6,
caused by tandem duplications in HCC1954 and PD4005a
(Figure S4).
We examined the protein-reading frame of transcripts arising
from gene fusions and within-gene rearrangements that
spanned more than one intron (Figure 4B). In 133 of 501 (27%)
such events, the resulting exon structure would be predicted
to generate an in-frame gene from transcript isoforms reported
in Ensembl; we found RNA-seq reads supporting these in-frame
transcripts in 35 of 133 (26%). Of the 368 rearrangements pre-2038 Cell Reports 16, 2032–2046, August 16, 2016dicted to be out of frame or involve the
non-coding UTR, we found evidence for
in-frame transcripts in 25 (7%). In many
cases, the in-frame transcript was more
heavily expressed than the canonical,
out-of-frame transcript, suggesting that
nonsense-mediated decay may be acting
on the latter (Figure 4C). Overall then,
these data indicate that 60 of 501 (12%)
of genomic rearrangements reordering
exons of one or two genes in the same
orientation have the potential to generate
transcripts encoding in-frame proteins.
Many of these are expressed at appre-
ciable levels, mostly driven by the up-
stream regulatory apparatus.
Gene-to-Gene Fusions in Opposite
Transcriptional Orientation
We would expect half of the genomic re-
arrangements linking two genes to join
them in opposing orientation, which
would be split equally between gene
pairs pointing inwardly at each other
and gene pairs pointing away from eachother. In the former, the 50 regulatory apparatus and transcrip-
tional start site of both genes would be retained, and they could
start transcripts that would extend into the partner gene on the
antisense strand. We identified 171 somatic rearrangements
generating gene-to-gene fusions in opposite orientation, of
which 114 were pointing inward (50-to-50 orientation). While
there was not much evidence of aberrant transcription arising
from 30-to-30 fusions, we found an unexpectedly high frequency
of stable transcription at gene pairs pointing inwardly
(Figure 5A).
In total, 50 (44%) of all 50-to-50 rearrangements generated
transcripts that fused the sense portion of one gene with novel
exons on the antisense strand of the partner gene. Mostly, the
AC
B Figure 4. Rearrangements between and
within Genes
(A) Fusions caused by rearranged genes in the
same orientation are shown.
(B) Proportion of rearrangements predicted to lead
to an in-frame event contrasted to the proportion
actually expressing in-frame transcripts (top).
Characteristics of expressed fusions (bottom) are
shown.
(C) Many fusions are expressed in multiple iso-
forms.novel transcribed sequence from the antisense strand of the
distal gene mapped to intronic regions, although a few fusions
did generate transcripts that partially or fully overlapped with
exons (Figure 5B). This is to be expected since splice sites
are directional, so the GT.AG structure of an intron is not reca-
pitulated on the antisense strand. However, where one might
have expected the reads derived from the antisense strand to
be rather scattered, the antisense exons were, in fact, surpris-
ingly fixed (Figure 5C). That is, the antisense component of
the fusion transcript tended to reuse the same latent splice
acceptor and donor sites on the antisense strand. These were
almost always associated with consensus GT-AG splice sig-
nals. For a small number of examples, multiple antisense exons
were recurrently included in the transcript. None of these novel
antisense exons was seen in the absence of the given 50-to-50
rearrangement, suggesting that it is the genomic rearrangement
that unmasks the latent transcriptional potential of these
regions.
It is unclear what functional potential these sense-to-
antisense gene fusions might have. Notably, we found an
example involving the estrogen receptor, ESR1, which gener-Cell Repated transcripts linking the sixth exon
into a multiply spliced antisense tran-
script of SYNE1 (Figure 5C). Fusion tran-
scripts involving the same intron of ESR1
are recurrent in breast cancer, and there
is evidence they have important func-
tional consequences, largely conferred
by the C-terminally truncated estrogen
receptor (Li et al., 2013). There is also
a rearrangement that fuses the first
20 exons of the transcriptional co-
activator CREBBP to the antisense
strand of CLUAP1. CREBBP is a well-
known cancer gene that can be targeted
by inactivating point mutations (Pasqua-
lucci et al., 2011) or, in leukemias,
involved in canonical fusion genes (Ca-
mo´s et al., 2006).
Gene-to-Intergenic
Rearrangements
We identified 473 genomic rearrange-
ments that joined the 50 portion of a
gene to an intergenic region and 461rearrangements linking 30 ends of genes to intergenic space
(Figure 6A). As seen with the 30-to-30 gene-to-gene fusions,
in the absence of promoters, only one 30 gene-to-intergenic
rearrangement led to a detectable RNA transcript. In contrast,
16 (3.4%) of 50 gene-to-intergenic rearrangements led to
stable expression of abnormal transcripts related to the
rearrangement.
The predominant transcripts that resulted from these 50
gene-to-intergenic rearrangements were fusions linking the 50
portion of the broken gene to exon 2 of the first intact, sense
gene downstream of the breakpoint (Figure 6B). Occasionally,
splicing into novel intergenic exons or into exon 1 of the down-
stream gene was observed, but, compared to splicing into exon
2, these transcripts were infrequent and represented minor RNA
species. In general, the first exon of a gene commences with the
transcription start site and, therefore, does not contain a splice
acceptor site, explaining why 50 gene-to-intergenic rearrange-
ments fuse into exon 2. Since the first exon of many genes
carries the ATG that initiates translation, many of these gene-
to-intergenic rearrangements could translate into bona fide
fusion proteins. Indeed, we identified three fusion transcriptsorts 16, 2032–2046, August 16, 2016 2039
AB
C
(legend on next page)
2040 Cell Reports 16, 2032–2046, August 16, 2016
caused by gene-to-intergenic rearrangements that were poten-
tially in frame (Figure 6B). The length of the novel intron created
by these transcribed gene-to-intergenic fusions was typically in
the 50- to 100-kb range, but it could be as high as 250 kb
(Figure 6C).
Regions of Local Complexity
We defined a region of local complexity as any gene footprint
that contained two or more genomic rearrangements. Typically,
these represented sites of extensive genomic amplification,
such as around ERBB2 or CCND1, or they were regions of chro-
mothripsis, a mutational process generating tens to hundreds of
localized genomic rearrangements in a one-off catastrophic
event (Stephens et al., 2011). Given the complexity of the
genomic changes in many of these regions, a surprising number
of rearrangements led to measurable transcriptional conse-
quences (Figure 7A). Indeed, when compared with genes hit
by simple rearrangements, the fractions of rearrangements
from regions of local genomic complexity giving aberrant tran-
scripts were broadly similar. This suggests that the regulatory
apparatus enabling transcription initiation remains at least
partially intact in many of these heavily rearranged regions
and that the genomic structure supports the production of sta-
ble transcripts.
We found that the transcripts that arose in these regions often
represented an integration across multiple rearrangements (Fig-
ure 7B; Figure S5). In PD4107a, for example, we found a fusion
transcript that linked QKI to the antisense strand of TRPS1
(blue arc, Figure 7B), which was, in fact, driven by two in cis
genomic rearrangements linking QKI to ANKRD11 and then
ANKRD11 to TRPS1. Due to the massive number of rearrange-
ments sometimes found in these regions of local complexity,
there can be a considerable degree of aberrant transcription.
In PD4103a, for example, among the hundreds of clustered
rearrangements localized to a small number of genomic regions,
we found 12 different fusion transcripts as well as seven alterna-
tively spliced isoforms driven by within-gene rearrangements
(Figure S5).
DISCUSSION
The disturbed transcriptional landscape of cancer cells results
from three main forces: (1) direct, primary consequences of
somatic mutation; (2) coordinated, secondary gene expression
changes resulting from altered cellular signaling, transcrip-
tional regulation, and chromatin landscape; and (3) generalFigure 5. Antisense Expression Caused by Rearranged Genes in Oppo
(A) Stacked bar plot shows the number of expressed transcripts per sample resu
(B) The diversity of chimeric transcripts produced by gene-to-gene rearrangeme
gene pairs (green) are rarely expressed, whereas, surprisingly, sense-to-sense a
respectively). Transcripts are placed on the x axis according to the type of read jo
the x axis, and genes brought together only by exon-to-intron reads are on the l
(C) Examples of productive, stable antisense fusion transcripts. Plotted on the
arrangement breakpoints. Inmost cases, we observed a single donor gene, which
which expresses sequence from its antisense strand (red). Rarely are both prom
sense and antisense sequence). The fusions SZT2-SLC6A9 and SLC6A9-SZT2
features of traditional exons: they are stably expressed, around 200 bp, and areloss of transcriptional fidelity, manifesting as shorter 30
UTRs (Mayr and Bartel, 2009), retained introns, trans-splicing
(Li et al., 2008), and so on. Here we have concentrated on
dissecting the immediate impact that the repertoire of
somatic mutations has on the transcriptome in breast
cancer, exploring the rules that govern how the transcriptional
machinery interprets somatic mutation. In some ways, this is
the most straightforward analysis of a cancer transcriptome
to perform; the causation chain is short and, in theory,
predictable.
One striking conclusion of the analysis is that transcription,
once started, will attempt to complete. We found an unexpect-
edly high number of transcripts resulting from structural variants
that sow the 50 seeds of a gene, namely upstream enhancers,
promoter, and first few exons, into seemingly infertile ground,
such as intergenic space or the antisense strand of another
gene. Indeed, in our data, the fraction of such events generating
productive transcription was not dissimilar to that observed for
rearrangements predicted to cause canonical gene fusions. In
the case of gene-to-intergenic rearrangements, the transcrip-
tional machinery can scan many tens of kilobases in search of
a splice acceptor site, often contributed by the second exon of
a downstream intact gene in the same orientation. For sense-
to-antisense fusions, the sense transcript often splices into novel
exons within the gene footprint of the antisense gene. In one
example, this generated a truncated version of the estrogen re-
ceptor gene ESR1. Recently, it has been reported that fusion
transcripts arising from breaks in the same intron of ESR1 are
recurrent in breast cancer and can confer resistance to endo-
crine therapy (Li et al., 2013).
Another important observation is that the transcriptional
output of breast cancer cells is greater than the surrounding stro-
mal cells. Using a method that accounts for differences in tumor
purity, we found a striking anti-correlation between ER levels and
the number of expressed mutations. That is, tumors with high
levels of ER express fewer mutations than cancers with low
ER. We formally modeled this relationship and determined
that, for every 1%decrease in ER expression, 15moremutations
are expressed. As a breast cancer loses estrogen receptor
expression and becomes more transcriptionally active, it is
more likely to actually express its complement of somatic muta-
tions. For example, we found that TP53mutations aremore likely
to be expressed in ER than ER+ breast cancers (Figure S7B).
While speculative, this is of interest to researchers in the field
of immunotherapy, since somatic mutations can act as neoanti-
gens that trigger host immune responses. There are studiessite Orientation
lting from gene fusions in opposite orientation.
nts. The expression level of each transcript is plotted on the y axis. Tail-to-tail
nd sense-to-antisense fusions show similar levels of expression (blue and red,
ining the two genes. Genes adjoined by exonic reads are plotted to the right on
eft.
y axis are the read depths supporting the fusion. Hatched lines indicate re-
expresses sequence from its sense strand (yellow), and a single acceptor gene,
oters used, leading to reciprocal sense-antisense fusions (both genes express
are examples of a reciprocal pair. In general, antisense transcripts display
frequently spliced at GT-AG splice sites (asterisks).
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C Figure 6. Non-canonical Fusions Caused by
Gene-to-Intergenic Breakpoints
(A) Percentage of gene-to-intergenic rearrange-
ments causing fusions is shown.
(B) Length of the intron created is shown.
(C) Genes involved in non-canonical fusions. We
observed 18 fusions where a broken gene (donor)
splices to another gene (acceptor) that is itself
unbroken and often distant. These fusions can be
highly expressed (width of line) and cause in-frame
transcripts (red line).reporting strong associations between the number of neoanti-
gens and response to immunotherapy, and our data suggest
that such mutations are more likely to be expressed in ER-ve
or ER-low tumors.
It is a necessary condition of a somatic mutation to be onco-
genic that it induces some transcriptional consequence, but it
is far from sufficient. We found that 59% of exonic point muta-
tions are expressed and 11.6% of genomic rearrangements
(balanced and unbalanced) hitting a gene footprint generate
aberrant transcripts. These aberrant transcripts are polyadeny-
lated, stable, and have the potential to generate protein prod-
ucts. In the case of cancer, even those that generate proteins
will be mostly inconsequential to cell biology, although there
will be some that are oncogenic. In the case of species evolution,2042 Cell Reports 16, 2032–2046, August 16, 2016however, such a high proportion of
genomic rearrangements generating sta-
ble fusion transcripts, novel exons, and
splicing isoforms could readily provide a
substrate for further genomic evolution
over many generations.
Statistics
Statistical Model for Analyzing
Allele-Specific Expression of
Heterozygous Germline SNPs on
the X Chromosome
For every heterozygous SNP on the X
chromosome, we have an observed
count of transcripts expressing the refer-
ence allele and a count for those express-
ing the variant allele. For each SNP, we do
not know whether the reference allele
is on the active X chromosome (Xa) or
the inactive X chromosome (Xi) in the
tumor cells. We further assume that, in
the contaminating stromal cells, the ex-
pected proportion of cells with the refer-
ence allele on Xa is 50%.Wemodel these
data using a hierarchical Bayesian model,
where the distribution of the fraction of
reads deriving from tumor cells from
across all genes follows a Dirichlet
process.
We defineN as the number of heterozy-
gous germline SNPs on the X chromo-some in a given sample and ni; i = 1;.;N as the total number
of reads across SNP i, of which yi report the reference allele.
Then yi  Binðni;piÞ, where pi is the expected proportion
of reads reporting the reference allele. Here pi follows a
mixture model depending on whether the reference allele is on
Xa or Xi.
fðpiÞ= lipi + ð1 piÞ=2;
where pi is the fraction of transcripts derived from tumor cells for
SNP i, and
li =

1; if reference allele is on Xa
0; if reference allele is on Xi:
AB
Figure 7. Regions of Local Complexity Give Rise to Unique Transcriptional Consequences
A region of local complexity is any gene footprint that contains two ormore genomic rearrangements. Local complexity can occur in regions of chromothripsis and
high-level amplification.
(legend continued on next page)
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We let li  Bernð0:5Þ as the prior, with pi  DPðaP0Þ. We use
the stick-breaking representation of the Dirichlet process as
follows:
P=
XN
h= 1
uhdph ; with ph  P0;
where dp is a point mass at p, and uh is the weight of the hth
gene expression cluster (that is, effectively the proportion of
genes for which the fraction of transcripts deriving from tumor
cells is p. To capture the stick-breaking formulation, we let
kh =Vh
Q
l < hð1 VlÞ, with Vh  Betað1;aÞ. We set a practical
maximum number of clusters, C, as 40. As priors, we set
P0  Uð0;1Þ and a  Gð0:01;0:01Þ.
To model the posterior distribution of the Dirichlet process, we
use Gibbs sampling as described below.
Step 1: Allocating Each Gene to One of the Clusters. We set
indicator variables, Sief1;2;.;Cg, to denote allocation of gene
i to a cluster. The posterior distribution of these variables is
therefore
PrðSi = hjÞ=

Vh
P
l < hð1 VlÞ
 ni
yi

pyih;i

1 ph;i
niyi
PC
r =1

Vr
P
l < rð1 VlÞ
 ni
yi

pyir;i

1 pr;i
niyi;
where h= 1;2;.;C and ph;i = liph + ð1 phÞ=2.
Step 2: Updating the Stick-BreakingWeights. These are condi-
tionally conjugate beta posterior distributions as follows:
ðVhjÞ  Beta
 
1+
XN
i = 1
1ðSi = hÞ;a+
XN
i = 1
1ðSi > hÞ
!
;
where h= 1;.;C 1 and VC = 1.
Step 3: Updating the Fraction of Transcripts Deriving from Tumor
Cells. We want to generate draws from the posterior distribu-
tion of ðph j Þ. We use a Metropolis-Hastings algorithm with
beta proposal distribution to do this. So,
PrðphjÞa
2
64 ðð1+phÞ=2Þ
P
i:Si = h
li yi
x ðð1 phÞ=2Þ
P
i:Si =h
ð1liÞyi
x
ðð1+phÞ=2Þ
P
i:Si = h
ð1liÞðniyiÞ
x ðð1 phÞ=2Þ
P
i:Si = h
liðniyiÞ
3
75
= ðð1+phÞ=2Þ
P
i:Si =h
ð2li yili ni +niyiÞ
ðð1 phÞ=2Þ
P
i:Si = h
ðyi2li yi + li niÞ
and the proposal distribution is gðx j x0Þ=Betaðx0d; dð1 x0ÞÞ;
where d is a scale parameter to be fine-tuned by trial and error
to achieve a reasonable acceptance/rejection proportion.(A) Proportion of simple and complex rearrangements that lead to an expressed
(B) Regions of local complexity and their transcriptional consequences. Two sam
events one would predict to be expressed are highlighted (blue arcs). Often
rearrangements and express a transcript that combines genes only indirectly link
2044 Cell Reports 16, 2032–2046, August 16, 2016Then the importance ratio for the jump from pðt1Þ to the pro-
posed p is given by
Prðp j Þ
Prðpðt1ÞÞ
g

pðt1Þ
p
gðp jpðt1ÞÞ :
Step 4: Updating the Indicator Variables of Whether the
Reference Allele Is on Xa or Xi. With a little algebra, this can
be shown to follow
Prðli = 1jÞ= 1
, 
1+

1 ph
1+ph
2yini!
:
Step 5: Updating the Hyperparameter. The posterior distribu-
tion for a is
ðajÞ  G
 
C+A 1; B
XC1
l = 1
logð1 VlÞ
!
;
where the prior is a  GðA;BÞ.
Statistical Analysis of Relationship between Variant
Allele Fractions in the Genome and Transcriptome for
Different Classes of Somatic Substitution
We fitted linear mixed-effects models to the variant allele frac-
tions. The variant allele fraction of reads reporting the mutant
allele was the dependent variable. The random effect was the
patient fromwhom the RNA sample derived, allowing for inter-in-
dividual differences in both the intercept and slope of the line
correlating genomic with transcriptomic variant allele fraction.
The fixed effects were the genomic variant allele fraction and
class of variant, with the main hypothesis of interest being
whether the relationship between genomic and transcriptomic
allele fraction differed across the classes of variant. This was
tested by adding class of variant-by-slope interaction terms to
the model, using likelihood ratio tests to assess for improved
fit. Models were fitted using maximum likelihood methods.EXPERIMENTAL PROCEDURES
Detection of Changes to Gene Transcript Structure
We developed a suite of tools for the analysis of cancer RNA-seq data, called
RNA Architect, comprised of several algorithms.
RNA Architect’s central component is a seed-and-extend algorithm used to
find reads that span disparate regions of the genome. These are junction reads
that provide the breakpoint between non-adjacent loci of fusion genes or alter-
native splice forms.We describe below howwe obtained these highly informa-
tive split reads by pre-filtering; grouping the reads into common events; and
then classifying, annotating, and filtering the high-confidence events (Figures
S1A and S1B).
(1) Pre-filter. We first removed any read that mapped normally to a genic
region in the human genome (build 37). That is, the read was fully con-
tained in an exon or was split across adjacent exons. We also excludedtranscript, grouped by sample, is shown.
ples’ regions of complexity are shown as pairs of Circos plots. The genomic
the tumors do not express these events, or they amalgamate multiple cis
ed to another.
read pairs if one end mapped to the mitochondria or if it contained two
or more unknown nucleotides (N). The pre-filtering step was performed
by aligning all reads to a transcriptome reference containing known
exons derived from Ensembl (using a modified version of BWA 0.5.9).
(2) Index. Having removed all of the reads involving known transcriptional
events, we ran a sensitive alignment of the remaining reads. We first
scanned the human genome, and we built an index containing the po-
sitions of all exons of all protein-coding genes, pseudogenes (including
polymorphic pseudogenes), and processed transcripts. We used a
word size of 9 bp as this provided the best balance between sensitivity
and run time.
(3) Shatter reads and align k-mers.We then shattered the 75-bp reads into
k-mers (13 bp), yielding five k-mers of equal size and one short k-mer
containing the 30 end of the read (the lowest quality portion of Illumina
reads). All k-mers were then aligned to the indexed genes without al-
lowing for any mismatches.
(4) Merge and extend. K-mers that map to adjacent positions were
merged into a single fragment. The k-mers that did not map are those
that spanned a breakpoint (inter- or intragenic). We then extended
mapped fragments into their unmapped neighbors, one base at a
time. We iteratively added bases to the k-mers, and we removed
them from the unmapped neighbors, until all fragments mapped to a
unique location and we successfully resolved the breakpoints. At this
point we allowed mismatches (SNPs, substitutions, or indels) only if
they were proceeded by a 2-bp perfect match to the reference.
(5) Clean. Most fusions and aberrant splice breakpoints were resolved us-
ing the methods outlined above. However, if a fragment remained un-
mapped, we tried to map it using modified parameters. If there existed
homologous sequences between both edges of the breakpoints, lead-
ing to ambiguity over where the breakpoint should be positioned, we
chose the breakpoint pair that yielded a junction spanning canonical
donor-acceptor sequences (GT-AG).
(6) Annotate. Having resolved the breakpoints of all fusion genes, aberrant
splice forms, and compound events, Architect writes junction coordi-
nates into a database (SQLite) and the split reads into a binary align-
ment file (BAM). Each event, which represents the junction of two or
more expressed sequences that are not normally found to be adjacent,
was ranked across a number of measures, including whether the event
is seen in normal samples or in the reference genome; the number of
reads supporting the event (total and unique); the sequence context
of the junction (i.e., whether canonical donor-acceptor sequences
are used); the average number of unique bases per read; and the num-
ber of reads mapped in the direct and reverse complemented orienta-
tion. We then implemented separate processes that used these mea-
sures to arrange the events into the following biologically meaningful
categories:
(A) Exon skips. A junction between two non-adjacent exons from the
same transcript, not found in normal organoids (less than two
reads) or in Ensembl, where the first exon is 5 prime to the second
exon. Exon skips were annotated to the Ensembl transcript that
involved the fewest number of exons lost. We required a split for-
ward read and a split reverse read to call an exon skip. We subca-
tegorized exon skips into those that involved the canonical edges
of the exons and those that involved a cryptic splice site (either 50 or
30 of the donor or acceptor site).
(B) Exon reusages. A junction between two non-adjacent exons from
the same transcript, not found in normal organoids (less than two
reads) or in Ensembl, where the first exon is 3 prime to the second
exon. Exon reusages were reported only if there were no Ensembl
transcripts that would explain the junction between the exons. We
recorded the number of exons reused and required a split forward
read and a split reverse read to call an exon reusage. We subcate-
gorized exon reusages into those that involved the canonical
edges of the exons and those that involved a cryptic splice site
(either 50 or 30 of the donor or acceptor site).
(C) Alternative donors and acceptors. A junction between two exons
thatbegins 50 or30 fromthecanonical exon-intronborder.Alternativedonor and acceptor sites can involve the extension of the exon into
the adjacent intron or the reduction of the exon. The junction must
not be found innormalorganoids (less than two reads) or inEnsembl,
and it must involve canonical donor-acceptor sequences (GT-AG).
(D) Earlypolyadenylationsites.A junctionbetween theexonofaprotein-
coding gene and a non-templated run of adenines (or thymines if
mapped to the opposite strand), which does not occur at the canon-
ical edgeof thegene’sUTR.The junctionsmustbe>10bpaway from
the canonical edge, and theymust not be found in normal organoids
(less than two reads) or in Ensembl.We subcategorized early polya-
denylation sites into those in UTRs and those in coding exons.
(E) Fusions genes. A junction between the exons of two protein-coding
genes that isnot found incontrol samples.Wehad twoapproaches to
finding fusion gene pairs: (1) using aberrant junctions that were split
across a breakpoint joining two genes, and (2) using read pairs that
were fully mapped (i.e., not split) to both genes. The first approach
used the seed-and-extend algorithm outlined above. The second
approach used a bespoke discordant-pair analysis algorithm, which
involved remapping the initially unmapped reads as singletons, re-
pairing them together, and evaluating whether there existed clusters
of read pairs aligning to two genes in a consistent manner.Weonly reported high-confidence fusion genes. These had to have been de-
tected by both the seed-and-extend algorithm and the discordant-pair algo-
rithm or detected by the discordant-pair algorithm alone with extremely
high ranking. This ranking was determined by evaluating the following: how
many reads map to other locations in the transcriptome (multi-mappings),
the consistency of the mapping positions (percentage of coefficient of varia-
tion <25), the number of unique reads in each gene (more than five), and the
consistency of the discordant read pairs’ orientation (<5% inconsistent). We
excluded reads where one end maps to the mitochondria. We subcategorized
fusion genes based on the relative orientation of the genes involved (same
orientation, or in opposite orientation [antisense]) and whether the fusion
also involved a cryptic splice site.
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